Sentinel Oncology: PhoreMost and Sentinel Oncology expand collaboration to jointly accelerate novel glioma therapeutic through preclinical development.

Lead allosteric PLK1 inhibitor to progress through preclinical and IND enabling studies Cambridge UK 04 November 2019 PhoreMost Limited the UKbased biopharmaceutical company dedicated to drugging 'undruggable' disease targets and Senti...